Affitech A/S - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Affitech A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Affitech A/S - Product Pipeline Review - 2014', provides an overview of the Affitech A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Affitech A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Affitech A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Affitech A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Affitech A/S's pipeline products

Reasons to buy

- Evaluate Affitech A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Affitech A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Affitech A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Affitech A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Affitech A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Affitech A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Affitech A/S Snapshot 5
Affitech A/S Overview 5
Key Information 5
Key Facts 5
Affitech A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Affitech A/S - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Affitech A/S - Pipeline Products Glance 16
Affitech A/S - Clinical Stage Pipeline Products 16
Phase I Products/Combination Treatment Modalities 16
Affitech A/S - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Affitech A/S - Unknown Stage Pipeline Products 19
Unknown Products/Combination Treatment Modalities 19
Affitech A/S - Drug Profiles 20
AT-001 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
EP-1300 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
AT-006 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AT-008 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PGN-635 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AT-009 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Inhibit GPCR for Inflammation and Oncology 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AT-004 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AT-005 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Affitech A/S - Pipeline Analysis 30
Affitech A/S - Pipeline Products by Target 30
Affitech A/S - Pipeline Products by Route of Administration 31
Affitech A/S - Pipeline Products by Molecule Type 32
Affitech A/S - Pipeline Products by Mechanism of Action 33
Affitech A/S - Recent Pipeline Updates 34
Affitech A/S - Dormant Projects 36
Affitech A/S - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Affitech A/S, Key Information 5
Affitech A/S, Key Facts 5
Affitech A/S - Pipeline by Indication, 2014 8
Affitech A/S - Pipeline by Stage of Development, 2014 9
Affitech A/S - Monotherapy Products in Pipeline, 2014 10
Affitech A/S - Partnered Products in Pipeline, 2014 11
Affitech A/S - Partnered Products/ Combination Treatment Modalities, 2014 12
Affitech A/S - Out-Licensed Products in Pipeline, 2014 13
Affitech A/S - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Affitech A/S - Phase I, 2014 16
Affitech A/S - Preclinical, 2014 17
Affitech A/S - Discovery, 2014 18
Affitech A/S - Unknown, 2014 19
Affitech A/S - Pipeline by Target, 2014 30
Affitech A/S - Pipeline by Route of Administration, 2014 31
Affitech A/S - Pipeline by Molecule Type, 2014 32
Affitech A/S - Pipeline Products by Mechanism of Action, 2014 33
Affitech A/S - Recent Pipeline Updates, 2014 34
Affitech A/S - Dormant Developmental Projects,2014 36
Affitech A/S, Other Locations 37